BMO Capital maintained an Outperform rating on Biogen (NASDAQ: BIIB) with a price target of $511. The stock dropped over ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View Hot Comments Trader Talk

Biogen (BIIB) Price Target Lifted to $422 at UBS Despite Caution on Tecfidera EstimatesApril 27, 2015 10:41 AM Biogen (BIIB) Misses Q1 EPS by 6c; Revs LightApril 24, 2015 7:01 AM Biogen Reports First Quarter 2015 Revenues of $2.6 BillionApril 24, 2015 7:00 AM